We are live on ! Find out more
ALPN

Alpine Immune Sciences Inc

Delisted

ALPN was delisted on the 17th of May, 2024.

76 hedge funds and large institutions have $380M invested in Alpine Immune Sciences Inc in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 2

183% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 12

42% more capital invested

Capital invested by funds: $268M → $380M (+$113M)

27% more funds holding

Funds holding: 6076 (+16)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
76
Holders Change
+16
Holders Change %
+26.67%
% of All Funds
1.19%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
18
Increased
34
Reduced
12
Closed
2
Calls
$52K
Puts
Net Calls
+$52K
Net Calls Change
+$52K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$48.2M +$27.6K +3,063 +0.1%
O
2
OrbiMed
New York
$42M
GPP
3
Great Point Partners
Connecticut
$34.6M -$3.4M -377,073 -10%
FLSM
4
Frazier Life Sciences Management
California
$30.7M
LCM
5
Lynx1 Capital Management
Puerto Rico
$27.5M -$4.2M -465,701 -15%
PBA
6
Paradigm Biocapital Advisors
New York
$24.9M +$959K +106,327 +5%
BlackRock
7
BlackRock
New York
$23.5M +$6.57M +728,772 +47%
OFM
8
Omega Fund Management
Massachusetts
$20.9M
Vanguard Group
9
Vanguard Group
Pennsylvania
$14.4M +$309K +34,258 +3%
CC
10
Commodore Capital
New York
$13.6M
AG
11
Artal Group
Luxembourg
$12.3M
APM
12
Avidity Partners Management
Texas
$10.9M +$622K +69,000 +7%
VC
13
Vivo Capital
California
$9.41M +$8.25M +914,913 New
OCA
14
Octagon Capital Advisors
New York
$7.71M -$4.08M -452,000 -38%
Fidelity Investments
15
Fidelity Investments
Massachusetts
$6.95M +$6.08M +674,330 +53,689%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$6.35M +$557K +61,767 +11%
State Street
17
State Street
Massachusetts
$5.89M +$2.04M +226,171 +65%
GTC
18
Ghost Tree Capital
New York
$3.57M +$1.33M +147,432 +74%
TLP
19
Tri Locum Partners
New York
$3.41M +$2.99M +331,992 New
Renaissance Technologies
20
Renaissance Technologies
New York
$3.28M -$99.2K -11,000 -3%
Northern Trust
21
Northern Trust
Illinois
$2.65M +$573K +63,537 +33%
TCM
22
TCG Crossover Management
California
$2.6M
WP
23
Woodline Partners
California
$2.44M +$2.14M +237,564 New
SFM
24
Sphera Funds Management
Israel
$2.06M
Walleye Capital
25
Walleye Capital
New York
$1.69M +$1.18M +130,556 +383%

ALPN Hedge Fund Activity: Q2 2023 in Review

76 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q2 2023, worth a combined $380M — up 42% from $268M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ALPN positions and 2 closed out — a net gain of 16 holders — while 34 added to existing stakes and 12 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $8.25M. The largest seller was BVF Inc, exiting entirely with an estimated $6.63M sold.

  • 76 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q2 2023, up from 60 in Q1 2023.
  • Funds reported $380M of Alpine Immune Sciences Inc stock for Q2 2023, up 42% quarter-over-quarter.
  • 18 funds opened new Alpine Immune Sciences Inc positions in Q2 2023 and 2 closed out, a net change of +16 holders.
  • The largest Alpine Immune Sciences Inc buyer in Q2 2023 was Vivo Capital, an estimated $8.25M added.
  • The largest Alpine Immune Sciences Inc seller in Q2 2023 was BVF Inc, an estimated $6.63M sold.

Based on aggregated 13F filings for Q2 2023.